Simulect ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
66IgA腎症1
97潰瘍性大腸炎8

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02523768
(ClinicalTrials.gov)
January 8, 20114/8/2015Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentPrevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentGlomerulonephritis;IgANDrug: ATG-F;Drug: SimulectCentre Hospitalier Universitaire de Saint EtienneNULLTerminated18 Years75 YearsAll117Phase 4France

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-004303-19-BE
(EUCTR)
08/06/200707/02/2007A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Czech Republic;United Kingdom;Belgium
2EUCTR2006-006319-54-BE
(EUCTR)
24/05/200708/02/2007An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135United Kingdom;Belgium
3EUCTR2006-006319-54-CZ
(EUCTR)
14/05/200720/02/2007An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Phase 2Czech Republic;Belgium;United Kingdom
4EUCTR2006-004303-19-CZ
(EUCTR)
09/05/200720/02/2007A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
181United Kingdom;Czech Republic;Belgium
5EUCTR2006-006319-54-SK
(EUCTR)
07/05/200708/03/2007An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Phase 2Czech Republic;Slovakia;Belgium;United Kingdom
6EUCTR2006-004303-19-SK
(EUCTR)
04/05/200708/03/2007A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
181Phase 2Czech Republic;Slovakia;Belgium;United Kingdom
7EUCTR2006-006319-54-GB
(EUCTR)
25/04/200707/12/2006An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
135 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noCzech Republic;Slovakia;Belgium;United Kingdom
8EUCTR2006-004303-19-GB
(EUCTR)
25/04/200706/12/2006A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 Steroid-refractory ulcerative colitis
MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative
Trade Name: Simulect
Product Name: Basiliximab
Other descriptive name: Basiliximab
Cerimon Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
135Phase 2Czech Republic;Slovakia;Belgium;United Kingdom